Skip to content
Screener

Kiniksa Pharmaceuticals International, plc KNSA Total Current Liabilities

Total Current Liabilities at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$46.74M-27.8%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$71.33M-18.5%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$99.89M+27.6%
Cytokinetics logo
CytokineticsCYTK
$181.43M+38.4%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$70.22M-0.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$816.37M+437%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+146%
Enterprise value$5.8B+159%
P/E74×-432×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0×0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemJune 30, 2026December 31, 2025
Accrued expenses46,73042,020
Operating lease liabilities4,0122,987
Other current liabilities20,05222,134
Total current liabilities171,247139,184
Non-current liabilities:
Non-current deferred revenue31,81131,811
Non-current operating lease liabilities4,8856,510
Other long-term liabilities34,01818,522

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's total current liabilities?
Kiniksa Pharmaceuticals International, plc (KNSA) reported total current liabilities of $171.25M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's total current liabilities changed year-over-year?
Kiniksa Pharmaceuticals International, plc's total current liabilities increased by 45.3% year-over-year, from $117.83M to $171.25M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's total current liabilities?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's total current liabilities has grown at a 34.3% compound annual growth rate (CAGR), from $31.85M to $139.18M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.

Ask your AI about Kiniksa Pharmaceuticals International, plc's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude